Lung Cancer Panel 7 (EGFR, BRAF, ALK1, ROS1, MET) – Comprehensive Genetic Testing
Understanding the Lung Cancer Panel 7 Test
The Lung Cancer Panel 7 represents a cutting-edge molecular diagnostic approach that revolutionizes lung cancer treatment by identifying specific genetic mutations driving tumor growth. This comprehensive panel examines five crucial biomarkers that have transformed how oncologists approach non-small cell lung cancer (NSCLC) management. By detecting EGFR, BRAF, ALK1, ROS1, and MET mutations, this test provides critical information for developing personalized treatment strategies that target the specific molecular drivers of each patient’s cancer.
What This Test Measures and Detects
Our advanced Lung Cancer Panel 7 utilizes sophisticated laboratory techniques including FISH (Fluorescence In Situ Hybridization) and Sanger Sequencing to identify specific genetic alterations:
- EGFR Mutations: Detects epidermal growth factor receptor mutations that respond to EGFR tyrosine kinase inhibitors
- BRAF Mutations: Identifies BRAF V600E and other mutations that may respond to targeted BRAF inhibitors
- ALK1 Rearrangements: Screens for ALK gene fusions that are highly responsive to ALK inhibitors
- ROS1 Rearrangements: Detects ROS1 gene fusions that respond to specific targeted therapies
- MET Amplifications: Identifies MET gene amplifications that may benefit from MET inhibitors
Who Should Consider This Test
This comprehensive genetic panel is particularly beneficial for patients with:
- Newly diagnosed non-small cell lung cancer, especially adenocarcinoma
- Advanced or metastatic lung cancer requiring treatment planning
- Previous treatment failure with conventional chemotherapy
- Family history of lung cancer or genetic predisposition
- Need for targeted therapy options beyond standard treatments
- Recurrent lung cancer requiring updated molecular profiling
Key Benefits of Genetic Testing for Lung Cancer
Undergoing the Lung Cancer Panel 7 provides numerous advantages for patients and healthcare providers:
- Personalized Treatment Selection: Identifies the most effective targeted therapies based on your tumor’s genetic profile
- Improved Treatment Outcomes: Targeted therapies often show better response rates and fewer side effects
- Comprehensive Molecular Profiling: Single test covering multiple actionable biomarkers
- Informed Clinical Decisions: Provides crucial information for treatment planning and prognosis
- Clinical Trial Eligibility: May identify opportunities for participation in targeted therapy trials
- Cost-Effective Approach: Comprehensive testing reduces the need for multiple individual tests
Understanding Your Test Results
Your Lung Cancer Panel 7 results will provide detailed information about the genetic mutations present in your tumor:
- Positive Results: Indicate the presence of specific mutations that may respond to targeted therapies
- Negative Results: Show no detectable mutations in the tested genes, suggesting alternative treatment approaches
- Variant of Unknown Significance: Some genetic changes may require additional interpretation
- Treatment Recommendations: Your oncologist will discuss appropriate targeted therapy options based on your results
It’s essential to review your results with your healthcare provider, who can explain the clinical implications and recommend the most appropriate treatment strategy based on your specific genetic profile.
Test Pricing and Information
| Test Name | Regular Price | Discount Price |
|---|---|---|
| Lung Cancer Panel 7 (EGFR, BRAF, ALK1, ROS1, MET) | $1200 USD | $900 USD |
Nationwide Testing Availability
We have diagnostic centers conveniently located across the United States, serving patients in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many other cities. Our network ensures accessible genetic testing services regardless of your location.
Take Control of Your Lung Cancer Treatment
Don’t leave your treatment decisions to chance. The Lung Cancer Panel 7 provides the critical genetic information needed to pursue targeted, personalized therapy options that can significantly improve your treatment outcomes. With results available in just 5-7 days from paraffin-embedded tissue samples, you can quickly move forward with the most appropriate treatment strategy.
Ready to get started? Call or WhatsApp us today at +1(267) 388-9828 to schedule your Lung Cancer Panel 7 test and take the first step toward personalized cancer care.
Note: This test requires a doctor’s prescription for most cases. Prescription requirements do not apply to surgery, pregnancy, or international travel scenarios. Please consult with your healthcare provider to determine if this test is appropriate for your specific situation.
